-
Je něco špatně v tomto záznamu ?
Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma
FC. Franke, A. Damek, J. Steglich, L. Kurch, D. Hasenclever, TW. Georgi, WA. Wohlgemuth, C. Mauz-Körholz, D. Körholz, R. Kluge, J. Landman-Parker, WH. Wallace, A. Fosså, D. Vordermark, J. Karlen, A. Fernández-Teijeiro, M. Cepelova, T. Klekawka,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
PubMed
37243889
DOI
10.1002/pbc.30421
Knihovny.cz E-zdroje
- MeSH
- dítě MeSH
- fluorodeoxyglukosa F18 terapeutické užití MeSH
- Hodgkinova nemoc * diagnostické zobrazování farmakoterapie komplikace MeSH
- hyperplazie thymu * diagnostické zobrazování etiologie MeSH
- lidé MeSH
- lokální recidiva nádoru diagnostické zobrazování farmakoterapie MeSH
- lymfom * farmakoterapie MeSH
- nádory brzlíku * diagnostické zobrazování farmakoterapie komplikace MeSH
- počítačová rentgenová tomografie MeSH
- pozitronová emisní tomografie metody MeSH
- radiofarmaka MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Rebound thymic hyperplasia (RTH) is a common phenomenon caused by stress factors such as chemotherapy (CTX) or radiotherapy, with an incidence between 44% and 67.7% in pediatric lymphoma. Misinterpretation of RTH and thymic lymphoma relapse (LR) may lead to unnecessary diagnostic procedures including invasive biopsies or treatment intensification. The aim of this study was to identify parameters that differentiate between RTH and thymic LR in the anterior mediastinum. METHODS: After completion of CTX, we analyzed computed tomographies (CTs) and magnetic resonance images (MRIs) of 291 patients with classical Hodgkin lymphoma (CHL) and adequate imaging available from the European Network for Pediatric Hodgkin lymphoma C1 trial. In all patients with biopsy-proven LR, an additional fluorodeoxyglucose (FDG)-positron emission tomography (PET)-CT was assessed. Structure and morphologic configuration in addition to calcifications and presence of multiple masses in the thymic region and signs of extrathymic LR were evaluated. RESULTS: After CTX, a significant volume increase of new or growing masses in the thymic space occurred in 133 of 291 patients. Without biopsy, only 98 patients could be identified as RTH or LR. No single finding related to thymic regrowth allowed differentiation between RTH and LR. However, the vast majority of cases with thymic LR presented with additional increasing tumor masses (33/34). All RTH patients (64/64) presented with isolated thymic growth. CONCLUSION: Isolated thymic LR is very uncommon. CHL relapse should be suspected when increasing tumor masses are present in distant sites outside of the thymic area. Conversely, if regrowth of lymphoma in other sites can be excluded, isolated thymic mass after CTX likely represents RTH.
Department of Clinical Radiology University Hospital of Münster Münster Germany
Department of Medical Oncology and Radiotherapy Oslo University Hospital Oslo Norway
Department of Nuclear Medicine University of Leipzig Leipzig Germany
Department of Pediatric Hematology and Oncology Justus Liebig University Gießen Germany
Department of Pediatric Hematology and Oncology University Hospitals Leuven Leuven Belgium
Department of Radiation Oncology Medical Faculty of the Martin Luther University Halle Germany
Department of Radiation Oncology University Hospital Vienna Vienna Austria
Department of Radiology Diakoniekrankenhaus Halle Halle Germany
Department of Radiology University Hospital Halle Germany
Erasmus MC Sophia Children's Hospital Rotterdam The Netherlands
Institute of Medical Informatics Statistics and Epidemiology University of Leipzig Leipzig Germany
Karolinska University Hospital Astrid Lindgrens Childrens Hospital Stockholm Sweden
Pediatric Onco Hematology Unit Hospital Universitario Virgen Macarena Sevilla Spain
Pediatric Oncology and Hematology Department University Children's Hospital of Krakow Krakow Poland
Princess Màxima Center for Pediatric Oncology Utrecht The Netherlands
Service d'Hématologie Pédiatrique Hôpital Robert Debré Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010822
- 003
- CZ-PrNML
- 005
- 20230801132636.0
- 007
- ta
- 008
- 230718s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/pbc.30421 $2 doi
- 035 __
- $a (PubMed)37243889
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Franke, Friedrich Christian $u Department of Radiology, Diakoniekrankenhaus Halle, Halle (Saale), Germany
- 245 10
- $a Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma / $c FC. Franke, A. Damek, J. Steglich, L. Kurch, D. Hasenclever, TW. Georgi, WA. Wohlgemuth, C. Mauz-Körholz, D. Körholz, R. Kluge, J. Landman-Parker, WH. Wallace, A. Fosså, D. Vordermark, J. Karlen, A. Fernández-Teijeiro, M. Cepelova, T. Klekawka, A. Attarbaschi, F. Ceppi, A. Hraskova, A. Uyttebroeck, A. Beishuizen, K. Dieckmann, T. Leblanc, M. Moellers, B. Buerke, D. Stoevesandt
- 520 9_
- $a BACKGROUND: Rebound thymic hyperplasia (RTH) is a common phenomenon caused by stress factors such as chemotherapy (CTX) or radiotherapy, with an incidence between 44% and 67.7% in pediatric lymphoma. Misinterpretation of RTH and thymic lymphoma relapse (LR) may lead to unnecessary diagnostic procedures including invasive biopsies or treatment intensification. The aim of this study was to identify parameters that differentiate between RTH and thymic LR in the anterior mediastinum. METHODS: After completion of CTX, we analyzed computed tomographies (CTs) and magnetic resonance images (MRIs) of 291 patients with classical Hodgkin lymphoma (CHL) and adequate imaging available from the European Network for Pediatric Hodgkin lymphoma C1 trial. In all patients with biopsy-proven LR, an additional fluorodeoxyglucose (FDG)-positron emission tomography (PET)-CT was assessed. Structure and morphologic configuration in addition to calcifications and presence of multiple masses in the thymic region and signs of extrathymic LR were evaluated. RESULTS: After CTX, a significant volume increase of new or growing masses in the thymic space occurred in 133 of 291 patients. Without biopsy, only 98 patients could be identified as RTH or LR. No single finding related to thymic regrowth allowed differentiation between RTH and LR. However, the vast majority of cases with thymic LR presented with additional increasing tumor masses (33/34). All RTH patients (64/64) presented with isolated thymic growth. CONCLUSION: Isolated thymic LR is very uncommon. CHL relapse should be suspected when increasing tumor masses are present in distant sites outside of the thymic area. Conversely, if regrowth of lymphoma in other sites can be excluded, isolated thymic mass after CTX likely represents RTH.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a dítě $7 D002648
- 650 12
- $a Hodgkinova nemoc $x diagnostické zobrazování $x farmakoterapie $x komplikace $7 D006689
- 650 12
- $a hyperplazie thymu $x diagnostické zobrazování $x etiologie $7 D013952
- 650 _2
- $a lokální recidiva nádoru $x diagnostické zobrazování $x farmakoterapie $7 D009364
- 650 12
- $a lymfom $x farmakoterapie $7 D008223
- 650 _2
- $a počítačová rentgenová tomografie $7 D014057
- 650 _2
- $a pozitronová emisní tomografie $x metody $7 D049268
- 650 12
- $a nádory brzlíku $x diagnostické zobrazování $x farmakoterapie $x komplikace $7 D013953
- 650 _2
- $a fluorodeoxyglukosa F18 $x terapeutické užití $7 D019788
- 650 _2
- $a radiofarmaka $7 D019275
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Damek, Adrian $u Department of Radiology, University Hospital Halle (Saale), Halle (Saale), Germany
- 700 1_
- $a Steglich, Jonas $u Department of Radiology, University Hospital Halle (Saale), Halle (Saale), Germany
- 700 1_
- $a Kurch, Lars $u Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany $1 https://orcid.org/0000000233964880
- 700 1_
- $a Hasenclever, Dirk $u Institute of Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany
- 700 1_
- $a Georgi, Thomas W $u Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
- 700 1_
- $a Wohlgemuth, Walther Alexander $u Department of Radiology, University Hospital Halle (Saale), Halle (Saale), Germany
- 700 1_
- $a Mauz-Körholz, Christine $u Department of Pediatric Hematology and Oncology, Justus-Liebig University, Gießen, Germany
- 700 1_
- $a Körholz, Dieter $u Department of Pediatric Hematology and Oncology, Justus-Liebig University, Gießen, Germany
- 700 1_
- $a Kluge, Regine $u Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
- 700 1_
- $a Landman-Parker, Judith $u Sorbonne Université/APHP hôpital Trousseau, Paris, France
- 700 1_
- $a Wallace, William Hamish $u Department of Paediatric Oncology, Royal Hospital for Sick Children, University of Edinburgh, Edinburgh, UK
- 700 1_
- $a Fosså, Alexander $u Department of Medical Oncology and Radiotherapy, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Vordermark, Dirk $u Department of Radiation Oncology, Medical Faculty of the Martin-Luther-University, Halle (Saale), Germany
- 700 1_
- $a Karlen, Jonas $u Karolinska University Hospital, Astrid Lindgrens Childrens Hospital, Stockholm, Sweden
- 700 1_
- $a Fernández-Teijeiro, Ana $u Pediatric Onco-Hematology Unit, Hospital Universitario Virgen Macarena, Sevilla, Spain
- 700 1_
- $a Cepelova, Michaela $u Department of Pediatric Hematology and Oncology, University Hospital Motol and Second Medical Faculty of Charles University, Prague, Czech Republic $1 https://orcid.org/000000017191588X
- 700 1_
- $a Klekawka, Tomasz $u Pediatric Oncology and Hematology Department, University Children's Hospital of Krakow, Krakow, Poland
- 700 1_
- $a Attarbaschi, Andishe $u Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000292856898
- 700 1_
- $a Ceppi, Francesco $u Division of Pediatrics, Department of Woman-Mother-Child, Pediatric Hematology-Oncology Unit, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland
- 700 1_
- $a Hraskova, Andrea $u Department of Pediatric Hematology and Oncology, National Institute of Paediatric Diseases, Bratislava, Slovakia
- 700 1_
- $a Uyttebroeck, Anne $u Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Beishuizen, Auke $u Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands $u Princess Màxima Center for Pediatric Oncology, Utrecht, The Netherlands
- 700 1_
- $a Dieckmann, Karin $u Department of Radiation Oncology, University Hospital Vienna, Vienna, Austria
- 700 1_
- $a Leblanc, Thierry $u Service d'Hématologie Pédiatrique, Hôpital Robert-Debré, Paris, France
- 700 1_
- $a Moellers, Martin $u Department Department of Pediatric Radiology, University Bielefeld, Campus Bielefeld-Bethel, Bielefeld, Germany
- 700 1_
- $a Buerke, Boris $u Department of Clinical Radiology, University Hospital of Münster, Münster, Germany
- 700 1_
- $a Stoevesandt, Dietrich $u Department of Radiology, University Hospital Halle (Saale), Halle (Saale), Germany $1 https://orcid.org/0000000151054488
- 773 0_
- $w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 70, č. 8 (2023), s. e30421
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37243889 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132633 $b ABA008
- 999 __
- $a ok $b bmc $g 1963318 $s 1197087
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 70 $c 8 $d e30421 $e 20230527 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
- LZP __
- $a Pubmed-20230718
